Clarify Remdesivir and Convalescent Plasma Use for COVID-19

You'll hear buzz about emergency use authorizations (EUAs) for remdesivir and convalescent plasma to treat COVID-19.

Remdesivir (Veklury). FDA is expanding the EUA to include ALL hospitalized patients with suspected or confirmed COVID-19.

But there currently isn't enough evidence to be certain of a benefit in nonsevere patients...and a 5-day course costs over $3,000.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote